Abstract
MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
| Original language | English |
|---|---|
| Pages (from-to) | 431-434 |
| Number of pages | 4 |
| Journal | Agents and Actions |
| Volume | 27 |
| Issue number | 3-4 |
| DOIs | |
| State | Published - Jun 1 1989 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Toxicology
- Pharmacology (medical)
Cite this
Pharmacological profile of MDL 26,024GO : A novel antiasthmatic agent. / Baugh, L.; Abraham, W.; Matthews, E.; Lahr, P.
In: Agents and Actions, Vol. 27, No. 3-4, 01.06.1989, p. 431-434.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacological profile of MDL 26,024GO
T2 - A novel antiasthmatic agent
AU - Baugh, L.
AU - Abraham, W.
AU - Matthews, E.
AU - Lahr, P.
PY - 1989/6/1
Y1 - 1989/6/1
N2 - MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
AB - MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
UR - http://www.scopus.com/inward/record.url?scp=0024406096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024406096&partnerID=8YFLogxK
U2 - 10.1007/BF01972843
DO - 10.1007/BF01972843
M3 - Article
C2 - 2801334
AN - SCOPUS:0024406096
VL - 27
SP - 431
EP - 434
JO - Inflammation Research
JF - Inflammation Research
SN - 1023-3830
IS - 3-4
ER -